• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas.

作者信息

Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, Nagashima K, Katoh H

机构信息

Second Department of Surgery, School of Medicine, Hokkaido University, Japan.

出版信息

Anticancer Res. 1999 May-Jun;19(3B):2257-60.

PMID:10472340
Abstract

BACKGROUND

Vascular endothelial growth factor (VEGF) is one of the most important factors for angiogenesis in various tumors. However, its clinical significance in extrahepatic biliary tract carcinoma remains unclear.

MATERIALS AND METHODS

To clarify the association of VEGF expression with the clinicopathological features of the disease, surgical specimens from 51 patients were examined for VEGF expression by immunohistochemistry.

RESULTS

Sixteen of 51 (31.4%) cases were positive for VEGF. VEGF immunoreactivity showed a tendency toward association with lymph node metastasis, M category and peritoneal recurrence (p = 0.059, 0.086 and 0.069, respectively). Overall survival in patients with VEGF positivity was significantly worse than in those with negativity (p = 0.033 by log-rank test). Multivariate Cox regression analysis revealed that VEGF expression was an independent negative predictor (p = 0.025).

CONCLUSION

VEGF immunoreactivity is an independent negative predictor in extrahepatic biliary tract carcinomas.

摘要

相似文献

1
Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas.
Anticancer Res. 1999 May-Jun;19(3B):2257-60.
2
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.血管内皮生长因子(VEGF)及其受体(Flt-1和Flk-1)在食管鳞状细胞癌中的表达
Anticancer Res. 2002 Nov-Dec;22(6C):3977-84.
3
Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.血管内皮生长因子表达可预测食管鳞状细胞癌的预后及淋巴结转移情况。
Clin Cancer Res. 2000 Mar;6(3):1161-8.
4
Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.未经治疗的骨肉瘤中血管内皮生长因子的表达可预测肺转移和预后不良。
Clin Cancer Res. 2000 Feb;6(2):572-7.
5
VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.血管内皮生长因子(VEGF)、fms样酪氨酸激酶-1(flt-1)和激酶插入区受体/胎儿肝脏激酶-1(KDR/flk-1)作为子宫内膜癌的预后指标
Gynecol Oncol. 2000 Jan;76(1):33-9. doi: 10.1006/gyno.1999.5658.
6
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.血管内皮生长因子、血小板衍生内皮细胞生长因子与非小细胞肺癌中的血管生成
Br J Cancer. 2000 Apr;82(8):1427-32. doi: 10.1054/bjoc.1999.1129.
7
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.血管内皮生长因子-C(VEGF-C)的表达可预测膀胱移行细胞癌的淋巴结转移。
Int J Urol. 2005 Feb;12(2):152-8. doi: 10.1111/j.1442-2042.2005.01010.x.
8
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?血管内皮生长因子(VEGF)能否预测接受放疗的淋巴结阴性乳腺癌的局部复发和生存率?
Br J Cancer. 1999 Oct;81(4):727-32. doi: 10.1038/sj.bjc.6690755.
9
Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma.I期肺腺癌中的肿瘤血管生成与血管内皮生长因子表达
Clin Cancer Res. 1998 Jun;4(6):1483-7.
10
Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis.血管内皮生长因子-C在人胆囊癌中的表达及其与淋巴结转移的关系。
Int J Mol Med. 2003 Jan;11(1):33-9.

引用本文的文献

1
Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.不可切除胆管癌的靶向治疗和免疫治疗
Chin Med J (Engl). 2025 Aug 20;138(16):1904-1926. doi: 10.1097/CM9.0000000000003705. Epub 2025 Jul 21.
2
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).阿昔替尼单药治疗吉西他滨为基础的化疗难治性晚期胆道癌的多中心 II 期临床试验(AX-BC 研究)。
Oncologist. 2021 Feb;26(2):97-e201. doi: 10.1002/onco.13547. Epub 2020 Oct 17.
3
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
新型及新兴的晚期胆管癌系统治疗选择。
Cells. 2020 Mar 11;9(3):688. doi: 10.3390/cells9030688.
4
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.在 UK ABC-03 试验中接受 Cediranib 治疗的晚期胆道癌患者治疗期间的循环生物标志物。
Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.
5
New Horizons for Precision Medicine in Biliary Tract Cancers.胆道肿瘤精准医学的新视野。
Cancer Discov. 2017 Sep;7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17.
6
Emerging molecular targets and therapy for cholangiocarcinoma.胆管癌的新兴分子靶点与治疗
World J Gastrointest Oncol. 2017 Jul 15;9(7):268-280. doi: 10.4251/wjgo.v9.i7.268.
7
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers.贝伐珠单抗联合吉西他滨和顺铂治疗晚期胆道癌可提高生存率。
Invest New Drugs. 2018 Feb;36(1):156-162. doi: 10.1007/s10637-017-0492-6. Epub 2017 Aug 1.
8
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.靶向胆管癌血管生成:一种可行选择。
Int J Mol Sci. 2017 Feb 15;18(2):418. doi: 10.3390/ijms18020418.
9
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.卡博替尼用于晚期胆管癌患者的2期及生物标志物研究。
Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13.
10
Immunotherapy of biliary tract cancer.胆管癌的免疫治疗
Tumour Biol. 2016 Mar;37(3):2817-21. doi: 10.1007/s13277-015-4743-x. Epub 2016 Jan 4.